Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.
University of California, Los Angeles
Summary
Glucagon like peptide (GLP-1) agonists, such as liraglutide, exenatide, and semaglutide, have been increasingly used as a medication to address the current twin epidemics of diabetes and obesity. Their activities include increasing insulin production by pancreatic beta cells, improving insulin sensitivity in muscles and weight loss. The mechanisms underpinning the weight loss caused by GLP-1 agonists have not yet been fully elucidated, but brown adipose tissue (BAT) appears to play an important role. We propose to assess BAT activity, using infrared thermography camera images, before individuals start weekly administration of semaglutide, at week 2-4, and week 18-20. We hypothesize that this GLP-1 agonist, semaglutide, will cause an increase in BAT activity and a corresponding increase in basal metabolic rate.
Description
Background and Rationale: Glucagon like peptide (GLP-1) agonists, such as liraglutide, exenatide, and semaglutide, have been increasingly used as a medication to address the current twin epidemics of diabetes and obesity. Their activities include increasing insulin production by pancreatic beta cells, improving insulin sensitivity in muscles and weight loss. The mechanisms underpinning the weight loss caused by GLP-1 agonists have not yet been fully elucidated, but brown adipose tissue (BAT) appears to play an important role. BAT is a type of adipose tissue which predominates in infants to a…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * Subjects scheduled to start semaglutide for weight loss (drug not provided by or paid for by the study) * \>18 years of age and willing to participate * Male or post-menopausal females Exclusion Criteria: * History of prior neck surgery and /or neck irradiation * Use of beta blocker agents * Use of any other glucose lowering medication * History of neuropathic disorders (e.g. diabetic neuropathy) * Diabetic patients * Individuals without normal thyroid function * Individuals with cancer * Any significant chronic disease or renal, hepatic or endocrine dis…
Interventions
- DrugSemaglutide Injectable Product (not provided by the study)
Study Procedure: Subjects that are to be started on semaglutide by their physician will be invited to participate in the study. If the subject is eligible and signs the consent form they will be enrolled in the study. There are three (3) study visits including Baseline/Visit 1 (prior to starting semaglutide), Visit 2 (at week 2-4) and Visit 3 (at week 18-20). The subjects undergo these tests at each visit: weight circumference measured, BMR testing, thermal imaging of BAT, and perform a 24 hour food recall.
Location
- UCLA HealthLos Angeles, California